Theravance Biopharma, Inc. Increase (Decrease) in Contract with Customer, Liability
Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Contract with Customer, Liability of -$216.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-03-07
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was -$199.00K.
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was -$6.00K.
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was -$5.00K.
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was -$6.00K.
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$216.00K.
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$192.00K.
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$11.46M.
- Theravance Biopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$26.46M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$205.00K derived: sum of 2 quarters · filed 2025-03-07 | -$210.00K derived: sum of 3 quarters · filed 2025-03-07 | -$216.00K 10-K · filed 2025-03-07 |
| 2023-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$11.00K derived: sum of 2 quarters · filed 2024-11-14 | -$17.00K 10-Q · filed 2024-11-14 | -$23.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$11.00K 10-Q · filed 2024-08-08 | -$17.00K derived: sum of 3 quarters · filed 2024-08-08 | -$23.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$6.00K 10-Q · filed 2024-05-15 | -$12.00K derived: sum of 2 quarters · filed 2024-05-15 | -$18.00K derived: sum of 3 quarters · filed 2024-05-15 | -$189.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$12.00K derived: sum of 2 quarters · filed 2024-03-01 | -$183.00K derived: sum of 3 quarters · filed 2024-03-01 | -$192.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$177.00K derived: sum of 2 quarters · filed 2023-11-09 | -$186.00K 10-Q · filed 2023-11-09 | -$3.00M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$180.00K 10-Q · filed 2023-08-09 | -$3.00M derived: sum of 3 quarters · filed 2023-08-09 | -$5.79M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$9.00K 10-Q · filed 2023-05-10 | -$2.82M derived: sum of 2 quarters · filed 2023-05-10 | -$5.62M derived: sum of 3 quarters · filed 2023-05-10 | -$7.60M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$5.61M derived: sum of 2 quarters · filed 2023-03-01 | -$7.59M derived: sum of 3 quarters · filed 2023-03-01 | -$11.46M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$4.78M derived: sum of 2 quarters · filed 2022-11-09 | -$8.65M 10-Q · filed 2022-11-09 | -$15.73M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$5.85M 10-Q · filed 2022-08-08 | -$12.94M derived: sum of 3 quarters · filed 2023-03-01 | -$20.20M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$3.87M 10-Q · filed 2022-05-06 | -$10.95M derived: sum of 2 quarters · filed 2023-03-01 | -$18.22M derived: sum of 3 quarters · filed 2023-03-01 | -$23.70M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$14.35M derived: sum of 2 quarters · filed 2023-03-01 | -$19.83M derived: sum of 3 quarters · filed 2023-03-01 | -$26.46M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$7.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$12.75M derived: sum of 2 quarters · filed 2021-11-08 | -$19.38M 10-Q · filed 2021-11-08 | -$28.97M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$12.12M 10-Q · filed 2021-08-05 | -$21.70M derived: sum of 3 quarters · filed 2022-02-28 | -$30.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$6.63M 10-Q · filed 2021-05-06 | -$16.22M derived: sum of 2 quarters · filed 2022-02-28 | -$25.05M derived: sum of 3 quarters · filed 2022-02-28 | -$32.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$9.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$18.42M derived: sum of 2 quarters · filed 2022-02-28 | -$25.91M derived: sum of 3 quarters · filed 2022-02-28 | -$31.25M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$8.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$16.33M derived: sum of 2 quarters · filed 2020-11-09 | -$21.66M 10-Q · filed 2020-11-09 | -$31.70M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$7.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$12.83M 10-Q · filed 2020-08-10 | -$22.87M derived: sum of 3 quarters · filed 2021-02-26 | -$31.86M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$5.33M 10-Q · filed 2020-05-08 | -$15.38M derived: sum of 2 quarters · filed 2021-02-26 | -$24.36M derived: sum of 3 quarters · filed 2021-02-26 | -$31.48M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$19.03M derived: sum of 2 quarters · filed 2021-02-26 | -$26.15M derived: sum of 3 quarters · filed 2021-02-26 | $69.22M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$8.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$16.11M derived: sum of 2 quarters · filed 2019-11-08 | $79.27M 10-Q · filed 2019-11-08 | $79.26M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$7.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $88.26M 10-Q · filed 2019-08-05 | $88.25M derived: sum of 3 quarters · filed 2020-02-27 | $88.26M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $95.37M 10-Q · filed 2019-05-10 | $95.37M derived: sum of 2 quarters · filed 2020-02-27 | $95.37M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $2.00K derived: sum of 2 quarters · filed 2020-02-27 | $17.00K 10-K · filed 2020-02-27 | |
| 2017-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $20.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $15.00K 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $448.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |